Business Context and Reporting Period
Company: Protara Therapeutics, Inc. (TARA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Primary Event: Disclosure of updated interim data from the Phase 2 open-label ADVANCED-2 Trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The data was presented at the ASCO Genitourinary Cancer Symposium on February 27, 2026.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details positive interim results for TARA-002 in two patient cohorts as of a January 28, 2026 data cutoff:
- BCG-Unresponsive Cohort (35 evaluable patients):
- Complete Response (CR) rate at any time: 65.7% (23/35).
- CR rate at 6 months: 68.2% (15/22).
- CR rate at 12 months: 33.3% (5/15).
- Re-induction success: 61.5% (8/13) of non-responders converted to CR at 6 months.
- BCG-Naïve Cohort (29 evaluable patients):
- Complete Response (CR) rate at any time: 72.4% (21/29).
- CR rate at 6 months: 66.7% (18/27).
- CR rate at 12 months: 57.9% (11/19).
- Re-induction success: 66.7% (4/6) of non-responders converted to CR at 6 months.
- Safety Profile: No Grade 3 or greater treatment-related adverse events (TRAEs) and no related serious adverse events. No patients discontinued due to TRAEs. Most common TRAEs were dysuria (14%) and bladder spasm (9%).
Guidance, Outlook, and Risks
Next Steps and Timeline:
- BCG-Unresponsive Cohort: Enrollment expected to complete in the second half of 2026.
- BCG-Naïve Cohort: Enrollment complete (31 patients).
- ADVANCED-3 Trial: Registrational trial in BCG-Naïve patients expected to initiate in the second half of 2026.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Key risks include the ability to obtain sufficient financing, the timing and outcome of clinical trials, regulatory interactions with the FDA, and general market conditions. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the full text of the Press Release (Exhibit 99.1) and Poster Presentations (Exhibits 99.4 and 99.5) for detailed statistical analysis.
- Confirm the company's current cash runway and financing status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor the timeline for the initiation of the ADVANCED-3 registrational trial in the second half of 2026.
- Review the safety data regarding the absence of Grade 3+ adverse events to assess the drug's risk profile for future regulatory approval.